2008
Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research 2008, 105: 1-9. PMID: 18774696, DOI: 10.1016/j.schres.2008.07.008.Peer-Reviewed Original ResearchConceptsNeuropsychological courseDouble-blind treatment studyNeuropsychological StatusPlacebo-assigned subjectsPutative prodromal stateDouble-blind trialFrank psychotic episodeEarly convertersOlanzapine treatmentNeuropsychological deficienciesFrank psychosisMedication studiesFirst episodePsychotic episodeProdromal stateHigh riskBlind trialNeuropsychological declineTreatment studiesPsychotic conditionsPsychosisLate convertersOlanzapineProdromeInitial assessment
2006
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal Of Psychiatry 2006, 163: 790-799. PMID: 16648318, DOI: 10.1176/ajp.2006.163.5.790.Peer-Reviewed Original ResearchConceptsOlanzapine patientsPlacebo patientsProdromal symptomsPsychosis ratesDouble-blind treatment periodEfficacy of olanzapineFurther treatment researchOlanzapine Versus PlaceboOlanzapine-treated patientsDouble-blind trialPhase of illnessPositive prodromal symptomsInduced Weight GainHazard of conversionSignificant differencesNorth American clinicsSignificant treatment differencesOlanzapine groupVersus PlaceboPlacebo groupSymptom scoresEfficacy measuresWeek 8Treatment periodPatients
2003
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 2003, 54: 453-464. PMID: 12915290, DOI: 10.1016/s0006-3223(03)00321-4.Peer-Reviewed Original ResearchConceptsExtrapyramidal symptomsPlacebo-controlled trialShort-term efficacyTrial of olanzapineTreatment x time interactionGreater symptomatic improvementSymptom total scoreX time interactionGreater weight gainRepeated-measures analysisOlanzapine patientsSchizophrenic prodromeOlanzapine treatmentPlacebo patientsSymptomatic improvementAcute treatmentMore patientsOlanzapine 5Prodromal symptomsRoutine treatmentProdromal patientsProdromal phaseWeek 8Week 6PlaceboThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design. Schizophrenia Research 2003, 61: 7-18. PMID: 12648731, DOI: 10.1016/s0920-9964(02)00439-5.Peer-Reviewed Original ResearchConceptsPsychosis onsetClinical trialsDouble-blind placebo-controlled clinical trialStudy rationaleDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsNew diagnostic criteriaClinical trial designPutative prodromal syndromeTreatment-seeking patientsOngoing symptomatologyNeuroleptic medicationHigh riskDiagnostic criteriaTrial designEarly courseProdromal SyndromesClinical phenomenologyStudy designClinical populationsPatientsOnsetIntervention researchTrialsThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample. Schizophrenia Research 2003, 61: 19-30. PMID: 12648732, DOI: 10.1016/s0920-9964(02)00440-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBenzodiazepinesBipolar DisorderComorbidityDepressive Disorder, MajorDouble-Blind MethodFemaleHumansMaleMood DisordersOlanzapinePirenzepinePsychomotor DisordersPsychotic DisordersRisk FactorsSchizophreniaSchizophrenic PsychologySleep Wake DisordersSpeech DisordersConceptsFirst-episode schizophreniaEpisode schizophreniaTreatment-seeking patientsClinical trialsDouble-blind placebo-controlled clinical trialProdromal SyndromesDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsMild affective symptomsNew diagnostic criteriaSerious mental illnessClinical trial samplesUntreated first-episode schizophreniaSubstance use/abuseEffects of drugsPutative prodromal syndromeUse/abuseUnusual thought contentAdolescent maniaOngoing symptomatologyProdromal sampleStudy medicationBaseline characteristicsMost patients